{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:13:45Z","timestamp":1779362025736,"version":"3.51.4"},"publisher-location":"Cham","reference-count":140,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030163907","type":"print"},{"value":"9783030163914","type":"electronic"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1007\/978-3-030-16391-4_3","type":"book-chapter","created":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T11:03:35Z","timestamp":1560769415000},"page":"81-108","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Role of Precision Medicine in the Diagnosis and Treatment of Patients with Rare Cancers"],"prefix":"10.1007","author":[{"given":"Michael J.","family":"Demeure","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,18]]},"reference":[{"key":"3_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4103\/ijmr.IJMR_915_14","volume":"145","author":"RK Pillai","year":"2017","unstructured":"Pillai RK, Jayasree K (2017) Rare cancers: challenges & issues. Indian J Med Res 145:17\u201327","journal-title":"Indian J Med Res"},{"issue":"1","key":"3_CR2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1177\/003335491012500106","volume":"125","author":"Robert T. Greenlee","year":"2010","unstructured":"Greenlee RT, Goodman MT, Lynch CF et al (2010) The occurrence of rare cancers in U.S. adults, 1995\u20132004. Public Health Rep 125:28\u201343","journal-title":"Public Health Reports"},{"key":"3_CR3","first-page":"41","volume":"28","author":"TC Tucker","year":"2001","unstructured":"Tucker TC, Howe HL (2001) Measuring the quality of population-based cancer registries: the NAACR perspective. J Reg Manag 28:41\u201344","journal-title":"J Reg Manag"},{"key":"3_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.4081\/rt.2014.5281","volume":"6","author":"E Trice Loggers","year":"2014","unstructured":"Trice Loggers E, Prigerson HG (2014) The end-of-life experience of patients with rare cancers and their caregivers. Rare Tumors 6:24\u201327","journal-title":"Rare Tumors"},{"key":"3_CR5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3322\/caac.21400","volume":"67","author":"CE DeSantis","year":"2017","unstructured":"DeSantis CE, Kramer JL, Jemal A (2017) The burden of rare cancers in the United States. CA Cancer J Clin 67:261\u2013272","journal-title":"CA Cancer J Clin"},{"key":"3_CR6","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S1470-2045(05)70471-X","volume":"7","author":"C Gatta","year":"2006","unstructured":"Gatta C, Ciccolallo L, Kunkler I et al (2006) Survival from rare cancer in adults: a population-based study. Lancet Oncol 7:132\u2013140","journal-title":"Lancet Oncol"},{"key":"3_CR7","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","volume":"366","author":"M Fassnacht","year":"2012","unstructured":"Fassnacht M, Terzolo M, Allolio B et al (2012) Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 366:2189\u20132197","journal-title":"N Engl J Med"},{"key":"3_CR8","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1002\/jso.23882","volume":"111","author":"SM Smith","year":"2015","unstructured":"Smith SM, Coleman J, Bridge JA, Iwenofu OH (2015) Molecular diagnostics in soft tissue sarcoma and gastrointestinal stromal tumors. J Surg Oncol 111:520\u2013531","journal-title":"J Surg Oncol"},{"issue":"2","key":"3_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1200\/JCO.2017.74.9374","volume":"36","author":"Inga-Marie Schaefer","year":"2018","unstructured":"Schaefer IM, Cote GM, Hornick JL (2017) Contemporary sarcoma diagnosis, genetics, and genomics. J Clin Oncol 36:101\u2013110","journal-title":"Journal of Clinical Oncology"},{"key":"3_CR10","volume-title":"WHO classification of tumours of soft tissue and bone","author":"CDM Fletcher","year":"2002","unstructured":"Fletcher CDM, Unni KK, Mertens F (2002) WHO classification of tumours of soft tissue and bone, 3rd edn. IARC Press, Lyon, France","edition":"3"},{"key":"3_CR11","volume-title":"WHO classification of tumours of soft tissue and bone","author":"CD Fletcher","year":"2013","unstructured":"Fletcher CD, Hogendoorn P, Mertens F, Bridge J (2013) WHO classification of tumours of soft tissue and bone, 4th edn. IARC Press, Lyon, France","edition":"4"},{"key":"3_CR12","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/S1470-2045(15)00583-5","volume":"17","author":"A Italiano","year":"2016","unstructured":"Italiano A, Di Mauro I, Rapp J et al (2016) Clinical effect of molecular methods in sarcoma diagnosis (GENSARC): a prospective, multicenter, observational study. Lancet Oncol 17:532\u2013538","journal-title":"Lancet Oncol"},{"key":"3_CR13","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1001\/jamaoncol.2016.5751","volume":"3","author":"H Joensuu","year":"2017","unstructured":"Joensuu H, Wardelmann E, Sihto H et al (2017) Effect of KIT and PDGFRA mutations on survival in patients with gastrointestinal stromal tumors treated with adjuvant imatinib: an exploratory analysis of a randomized clinical trial. JAMA Oncol 3:602\u2013609","journal-title":"JAMA Oncol"},{"key":"3_CR14","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1053\/hupa.2002.32216","volume":"33","author":"B Gunawan","year":"2002","unstructured":"Gunawan B, Bergmann F, H\u00f6er J et al (2002) Biological and clinical significance of cytogenetic abnormalities in low-risk and high-risk gastrointestinal stromal tumors. Hum Pathol 33:316\u2013321","journal-title":"Hum Pathol"},{"key":"3_CR15","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1200\/JCO.2005.05.3439","volume":"24","author":"CP Raut","year":"2006","unstructured":"Raut CP et al (2006) Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 24:2325\u20132331","journal-title":"J Clin Oncol"},{"key":"3_CR16","unstructured":"Gorthi A, Romero JC, Loranc E et al (2018) EWS-FL11 increases transcription to cause R-loops and block BRCA repair in Ewing sarcoma. Nature, 87\u2013391"},{"issue":"suppl_5","key":"3_CR17","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/nox158","volume":"19","author":"Quinn T Ostrom","year":"2017","unstructured":"Ostrom QT, Gittleman H, Liao P et al (2017) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010\u20132014. Neuro-Oncology 19(supp 5): v1\u2013v88","journal-title":"Neuro-Oncology"},{"key":"3_CR18","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.2353\/ajpath.2007.070011","volume":"170","author":"H Ohgaki","year":"2007","unstructured":"Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170:1445\u20131453","journal-title":"Am J Pathol"},{"key":"3_CR19","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1126\/science.1164382","volume":"321","author":"DW Parsons","year":"2008","unstructured":"Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807\u20131812","journal-title":"Science"},{"key":"3_CR20","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1056\/NEJMoa0808710","volume":"360","author":"H Yan","year":"2009","unstructured":"Yan H, Parsons W, Jim G et al (2009) IHD1 and IDH2 mutations in gliomas. N Engl J Med 360:765\u2013773","journal-title":"N Engl J Med"},{"key":"3_CR21","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ et al (2005) Cancer genome project: acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054\u20131061","journal-title":"Lancet"},{"key":"3_CR22","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1182\/blood-2008-02-138230","volume":"112","author":"CS Tam","year":"2008","unstructured":"Tam CS, Nussenzveig RM, Popat U et al (2008) The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood 112:1628\u20131637","journal-title":"Blood"},{"issue":"1","key":"3_CR23","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1182\/blood-2006-12-062125","volume":"110","author":"A. Theocharides","year":"2007","unstructured":"Theocharides A, Boissinot M, Girodon F et al (2007) Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 110:375\u2013379","journal-title":"Blood"},{"key":"3_CR24","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"A Vannucchi","year":"2015","unstructured":"Vannucchi A, Kiladjian JJ, Griesshammer M et al (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372:426\u2013435","journal-title":"N Engl J Med"},{"key":"3_CR25","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1309\/AJCPMORR5Z2IKCEM","volume":"144","author":"F Vega","year":"2015","unstructured":"Vega F, Medeiros LJ, Bueso-Ramos CE et al (2015) Hematolymphoid neoplasms associated with rearrangements of PDGFRA, PDGFRB, and FGFR1. Am J Clin Path 144:377\u2013392","journal-title":"Am J Clin Path"},{"key":"3_CR26","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1056\/NEJMoa020150","volume":"347","author":"JF Apperley","year":"2002","unstructured":"Apperley JF, Gardembs M, Melo JC et al (2002) Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 347:481\u2013487","journal-title":"N Engl J Med"},{"issue":"9","key":"3_CR27","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.3324\/haematol.11420","volume":"92","author":"M. Baccarani","year":"2007","unstructured":"Baccarani M, Cilloni D, Rondoni M et al (2007) The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 92:1173\u20131179","journal-title":"Haematologica"},{"key":"3_CR28","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1182\/blood-2003-08-2798","volume":"15","author":"AD Klion","year":"2004","unstructured":"Klion AD, Robyn J, Akin C et al (2004) Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 15:473\u2013478","journal-title":"Blood"},{"key":"3_CR29","doi-asserted-by":"publisher","first-page":"158","DOI":"10.4065\/mcp.2009.0503","volume":"85","author":"A Tefferi","year":"2010","unstructured":"Tefferi A, Gotlib J, Pardanani A (2010) Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. Mayo Clin Proc 85:158\u2013164","journal-title":"Mayo Clin Proc"},{"key":"3_CR30","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1136\/jcp.50.2.128","volume":"50","author":"D Wright","year":"1997","unstructured":"Wright D, McKeever P, Carter R (1997) Childhood non-Hodgkin lymphomas in the United Kingdom: findings from the UK Children\u2019s Cancer Study Group. J Clin Pathol 50:128\u2013134","journal-title":"J Clin Pathol"},{"key":"3_CR31","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1158\/2159-8290.CD-14-0377","volume":"4","author":"CM Lovly","year":"2014","unstructured":"Lovly CM, Gupta A, Lipson D et al (2014) Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. Cancer Discov 4:889\u2013895","journal-title":"Cancer Discov"},{"key":"3_CR32","doi-asserted-by":"crossref","unstructured":"Kwak EL, Bang YJ, Camidge Dr et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693\u20131703","DOI":"10.1056\/NEJMoa1006448"},{"issue":"28","key":"3_CR33","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1200\/JCO.2017.73.4830","volume":"35","author":"Yael P. Moss\u00e9","year":"2017","unstructured":"Moss\u00e9 YP, Voss SD, Lim MS et al (2017) Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: A Children\u2019s Oncology Group Study. J Clin Oncol 35:3215\u20133221","journal-title":"Journal of Clinical Oncology"},{"key":"3_CR34","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1053\/j.seminoncol.2016.02.008","volume":"43","author":"K Maddocks","year":"2016","unstructured":"Maddocks K, Jones JA (2016) Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia. Semin Oncol 43:251\u2013259","journal-title":"Semin Oncol"},{"key":"3_CR35","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"MC Byrd","year":"2013","unstructured":"Byrd MC, Furman RR, Coutre SE et al (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369:32\u201342","journal-title":"N Engl J Med"},{"key":"3_CR36","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","volume":"378","author":"JF Seymour","year":"2018","unstructured":"Seymour JF, Kipps TJ, Eichhorst B et al (2018) Venetoclax\u2013rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 378:1107\u20131120","journal-title":"N Engl J Med"},{"issue":"21","key":"3_CR37","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1101\/gad.1025302","volume":"16","author":"J. K. Chen","year":"2002","unstructured":"Chen JK, Taipale J, Cooper MK et al (2002) Inhibition of hedgehog signaling by direct binding of cyclopamine to smoothened. Genes Dev 16:2743\u20132748","journal-title":"Genes & Development"},{"key":"3_CR38","doi-asserted-by":"publisher","first-page":"6646","DOI":"10.1021\/jm8008508","volume":"51","author":"MR Tremblay","year":"2008","unstructured":"Tremblay MR, Nevalainen M, Nair SJ et al (2008) Semisynthetic cyclopamine analogues as potent and orally bioavailable hedgehog pathway antagonists. J Med Chem 51:6646\u20136649","journal-title":"J Med Chem"},{"key":"3_CR39","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1517\/17460441.2014.920816","volume":"9","author":"SE Gould","year":"2014","unstructured":"Gould SE, Low JA, Marsters JC Jr et al (2014) Discovery and preclinical development of vismodegib. Expert Opin Drug Discov 9:969\u2013984","journal-title":"Expert Opin Drug Discov"},{"key":"3_CR40","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1056\/NEJMoa0905360","volume":"361","author":"DD Hoff Von","year":"2009","unstructured":"Von Hoff DD, LoRusso PM, Rudin CM et al (2009) Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 361:1164\u20131172","journal-title":"N Engl J Med"},{"key":"3_CR41","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s12885-017-3286-5","volume":"17","author":"A Sekulic","year":"2017","unstructured":"Sekulic A, Migden MR, Basset-Sequin N et al (2017) Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer 17:332\u2013341","journal-title":"BMC Cancer"},{"key":"3_CR42","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0277-5379(90)90262-R","volume":"26","author":"P Pfeiffer","year":"1990","unstructured":"Pfeiffer P, Hansen RO, Rose C (1990) Systemic cytotoxic therapy of basal cell carcinoma: a review of the literature. Eur J Cancer 26:73\u201377","journal-title":"Eur J Cancer"},{"key":"3_CR43","first-page":"842","volume":"57","author":"C Raffel","year":"1997","unstructured":"Raffel C, Jenkins RB, Frederick L et al (1997) Sporadic medulloblastomas contain PTCH mutations. Cancer Res 57:842\u2013845","journal-title":"Cancer Res"},{"key":"3_CR44","doi-asserted-by":"crossref","unstructured":"Zeltzer PM, Boyett JM, Finlay JL et al (1999) Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions From the Children\u2019s Cancer Group 921 randomized phase III study 17:832\u2013845","DOI":"10.1200\/JCO.1999.17.3.832"},{"key":"3_CR45","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1200\/JCO.2014.60.1591","volume":"33","author":"GW Robinson","year":"2015","unstructured":"Robinson GW, Orr BA, Wu G et al (2015) Vismodegib exerts targeted efficacy against recurrent sonic hedgehog-subgroup medulloblastoma: Results from phase II pediatric brain tumor consortium studies PBTC-025B and PBTC-032. J Clin Oncol 33:2646\u20132654","journal-title":"J Clin Oncol"},{"key":"3_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21767\/2573-5365.100018","volume":"2","author":"RI Henkin","year":"2016","unstructured":"Henkin RI, Hosein S, Stateman WA, Knoppel AB (2016) Sonic Hedgehog in nasal mucous is a biomarker for smell loss in patients with hyposmia. Cell Mol Med 2:1\u20135","journal-title":"Cell Mol Med"},{"key":"3_CR47","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1126\/science.1226344","volume":"338","author":"G Iyer","year":"2012","unstructured":"Iyer G, Hanrahan AJ, Milowsky MI et al (2012) Genome sequencing identifies a basis for everolimus sensitivity. Science 338:221\u2013223","journal-title":"Science"},{"issue":"15","key":"3_CR48","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1128\/MCB.01578-08","volume":"29","author":"M. A. Lopez-Lago","year":"2009","unstructured":"L\u00f3pez-Lago MA, Okada T, Murillo MM et al (2009) Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol Cell Biol 29(15):4235\u201349","journal-title":"Molecular and Cellular Biology"},{"key":"3_CR49","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","volume":"371","author":"BJ Solomon","year":"2014","unstructured":"Solomon BJ, Mok T, Kim D-W et al (2014) First-Line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371:2167\u20132177","journal-title":"N Engl J Med"},{"key":"3_CR50","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","volume":"368","author":"AT Shaw","year":"2013","unstructured":"Shaw AT, Kim DW, Nakagawa K et al (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385\u20132394","journal-title":"N Engl J Med"},{"key":"3_CR51","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1007\/s00268-014-2485-3","volume":"38","author":"MJ Demeure","year":"2014","unstructured":"Demeure MJ, Aziz M, Rosenberg R, Gurley SD, Bussey KJ, Carpten JD (2014) Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target. World J Surg 38:1296\u20131305","journal-title":"World J Surg"},{"key":"3_CR52","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.1073\/pnas.1321937111","volume":"111","author":"LM Kelly","year":"2014","unstructured":"Kelly LM, Barila G, Liu P et al (2014) Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. Proc Natl Acad Sci 111:4233\u20134238","journal-title":"Proc Natl Acad Sci"},{"key":"3_CR53","doi-asserted-by":"publisher","unstructured":"Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C (2014) The landscape of kinase fusions in cancer. Nature Commun 5:4846. https:\/\/doi.org\/10.1038\/ncomms5846","DOI":"10.1038\/ncomms5846"},{"issue":"2","key":"3_CR54","doi-asserted-by":"publisher","first-page":"e000023","DOI":"10.1136\/esmoopen-2015-000023","volume":"1","author":"Alessio Amatu","year":"2016","unstructured":"Amatu A, Sartore-Bianchi A, Siena S (2016) NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open.1:e000023. eCollection 2016","journal-title":"ESMO Open"},{"key":"3_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1634\/theoncologist.2017-0001","volume":"22","author":"S Kato","year":"2017","unstructured":"Kato S, Kurasaki K, Ikeda S, Kurzrock R (2017) Rare Tumor Clinic: The University of California San Diego Moores Cancer Center experience with precision medicine approach. Oncologist 22:1\u20138","journal-title":"Oncologist"},{"key":"3_CR56","doi-asserted-by":"publisher","first-page":"4877","DOI":"10.1200\/JCO.2009.26.5983","volume":"28","author":"DD Hoff Von","year":"2010","unstructured":"Von Hoff DD, Stephenson JJ Jr, Rosen P et al (2010) Pilot study using molecular profiling of patients\u2019 tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 28:4877\u20134883","journal-title":"J Clin Oncol"},{"key":"3_CR57","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1200\/JOP.2016.011486","volume":"13","author":"DS Haslem","year":"2017","unstructured":"Haslem DS, Van Norman SB, Fulde G et al (2017) A retrospective analysis of precision medicine outcomes in patients with advanced cancer reveals improved progression-free survival without increased health care costs. J Oncol Pract 13:108\u2013119","journal-title":"J Oncol Pract"},{"key":"3_CR58","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","volume":"19","author":"MM Li","year":"2017","unstructured":"Li MM, Datto M, Duncavage EJ et al (2017) standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 19:4\u201323","journal-title":"J Mol Diagn."},{"key":"3_CR59","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S0140-6736(77)91415-5","volume":"309","author":"JD Rowley","year":"1977","unstructured":"Rowley JD, Golomb HM, Dougherty C (1977) 15\/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet 309:549\u2013550","journal-title":"Lancet"},{"key":"3_CR60","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1182\/blood-2007-07-102798","volume":"111","author":"YZ Wang","year":"2008","unstructured":"Wang YZ, Chen Z (2008) Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111:2505\u20132515","journal-title":"Blood"},{"key":"3_CR61","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1200\/JCO.2014.59.8433","volume":"33","author":"AJ Redig","year":"2015","unstructured":"Redig AJ, J\u00e4nne PA (2015) Basket trials and the evolution of clinical trial design in an era of genomic medicine. J Clin Oncol 33:975\u2013977","journal-title":"J Clin Oncol"},{"key":"3_CR62","unstructured":"Dangi-Garimella S (2017) Innovative approach to precision medicine trial: NCI-MATCH and Beat AML. Am J Manag Care 23:sp32\u2013sp33"},{"key":"3_CR63","doi-asserted-by":"crossref","unstructured":"Conley BA, Chen AP, O\u2019Dwyer PJ et al (2016) NCI-MATCH (Molecular Analysis for Therapy Choice): a national signal finding trial. J Clin Oncol 34:15_suppl, TPS2606","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS2606"},{"key":"3_CR64","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1200\/JCO.2016.69.9751","volume":"35","author":"KM Cunanan","year":"2017","unstructured":"Cunanan KM, Gonen M, Shen R et al (2017) Basket trials in oncology: a trade-off between complexity and efficiency. J Clin Oncol 35:271\u2013275","journal-title":"J Clin Oncol"},{"key":"3_CR65","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1001\/jamaoncol.2017.5029","volume":"4","author":"EL Diamond","year":"2018","unstructured":"Diamond EL, Subbiah B, Lockhart AC et al (2018) Vemurafenib for BRAF V600\u2013mutant Erdheim-Chester disease and Langerhans cell histiocytosis: Analysis of data from the histology-independent, phase 2, open-label VE-BASKET study. JAMA Oncol 4:384\u2013388","journal-title":"JAMA Oncol"},{"key":"3_CR66","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMoa1502309","volume":"373","author":"DM Hyman","year":"2015","unstructured":"Hyman DM, Puzanov I, Subbiah C et al (2015) Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 373:726\u2013736","journal-title":"N Engl J Med"},{"issue":"13","key":"3_CR67","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1182\/blood-2012-05-430140","volume":"120","author":"J. Haroche","year":"2012","unstructured":"Haroche J, Charlotte F, Arnaud L et al (2012) High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 120:2700\u20132703","journal-title":"Blood"},{"key":"3_CR68","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1158\/2159-8274.CD-10-0010","volume":"1","author":"ES Kim","year":"2011","unstructured":"Kim ES, Herbst RS, Wistuba II et al (2011) The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 1:44\u201353","journal-title":"Cancer Discov"},{"issue":"9","key":"3_CR69","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1200\/JCO.2014.58.2007","volume":"33","author":"A Lopez-Chavez","year":"2015","unstructured":"Lopez-Chavez A, Thomas A, Rajan A et al (2015) Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. J Clin Oncol 33(9):1000\u20131007","journal-title":"J Clin Oncol"},{"key":"3_CR70","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1200\/JCO.2015.61.5997","volume":"33","author":"M Schwaederle","year":"2015","unstructured":"Schwaederle M, Zhao M, Lee JJ et al (2015) Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials. J Clin Oncol 33:3817\u20133825","journal-title":"J Clin Oncol"},{"key":"3_CR71","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa1508054","volume":"373","author":"J Zhang","year":"2015","unstructured":"Zhang J, Walsh MF, Wu G et al (2015) Germline mutations in predisposition genes in pediatric cancer. N Engl J Med 373:2336\u20132346","journal-title":"N Engl J Med"},{"key":"3_CR72","unstructured":"Krishnan S, Basu G, Gonzalez-Malerva L et al (2016) Germline findings in targeted tumor sequencing using matched normal DNA. Cancer Res 76(14 Suppl), Abstract nr 4493"},{"key":"3_CR73","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1001\/jamaoncol.2015.5208","volume":"2","author":"KA Schrader","year":"2016","unstructured":"Schrader KA, Cheng DT, Joseph V et al (2016) Germline variants in targeted tumor sequencing using matched normal DNA. JAMA Oncol 2:104\u2013111","journal-title":"JAMA Oncol"},{"issue":"283","key":"3_CR74","doi-asserted-by":"publisher","first-page":"283ra53","DOI":"10.1126\/scitranslmed.aaa7161","volume":"7","author":"Si\u00e2n Jones","year":"2015","unstructured":"Jones S, Anagnostou V, Lytle K et al (2015) Personalized genomic analyses for cancer mutation discovery and interpretation. Sci Transl Med 7(283):283ra53. https:\/\/doi.org\/10.1126\/scitranslmed.aaa7161","journal-title":"Science Translational Medicine"},{"key":"3_CR75","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard CC, Mateo J, Walsh MF et al (2016) Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med 375:443\u2013453","journal-title":"N Engl J Med"},{"key":"3_CR76","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","volume":"373","author":"J Mateo","year":"2015","unstructured":"Mateo J, Carreira S, Sandhu S et al (2015) DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 373:1697\u20131708","journal-title":"N Engl J Med"},{"key":"3_CR77","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.eururo.2015.11.022","volume":"69","author":"HH Cheng","year":"2016","unstructured":"Cheng HH, Pritchard CC, Boyd T, Nelson PS, Montgomery B (2016) Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer. Eur Urol 69:992\u2013995","journal-title":"Eur Urol"},{"key":"3_CR78","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1093\/jnci\/90.8.606","volume":"90","author":"M Hisada","year":"1998","unstructured":"Hisada M, Garber JE, Fung CY, Fraumeni JF Jr, Li FP (1998) Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 90:606\u2013611","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"3_CR79","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.1002\/cncr.30248","volume":"122","author":"Phuong L. Mai","year":"2016","unstructured":"Mai PL, Best AF, Peters JA et al (2016) Risks of first and subsequent cancers among TP53 mutation carriers in the national cancer institute Li-Fraumeni syndrome cohort. Cancer 122:3673\u20133681","journal-title":"Cancer"},{"key":"3_CR80","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1001\/jamaoncol.2017.1968","volume":"3","author":"ML Ballinger","year":"2017","unstructured":"Ballinger ML, Best A, Pai ML et al (2017) Baseline surveillance in Li-Faumeni syndrome using whole-body magnetic resonance imaging: a meta-analysis. JAMA Oncol 3:1634","journal-title":"JAMA Oncol"},{"issue":"2","key":"3_CR81","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s10689-017-0034-6","volume":"17","author":"Jasmina Bojadzieva","year":"2017","unstructured":"Bojadzieva J, Amini B, Day SF et al (2018) Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni syndrome education and early detection (LEAD) clinic. Fam Cancer. 17:287\u2013294","journal-title":"Familial Cancer"},{"key":"3_CR82","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1001\/jamaoncol.2017.1350","volume":"3","author":"ML Pai","year":"2017","unstructured":"Pai ML, Kincha PP, Toud JT et al (2017) Prevalence of cancer at baseline screening in the national cancer institute Li-Fraumeni syndrome cohort. JAMA Oncol 3:1640","journal-title":"JAMA Oncol"},{"key":"3_CR83","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1136\/jcp.19.2.114","volume":"19","author":"ED Williams","year":"1966","unstructured":"Williams ED (1966) Histogenesis of medullary carcinoma of the thyroid. J Clin Pathol 19:114\u2013118","journal-title":"J Clin Pathol"},{"key":"3_CR84","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1308\/003588406X117043","volume":"88","author":"M Al-Rawi","year":"2006","unstructured":"Al-Rawi M, Wheeler MH (2006) Medullary thyroid cancer: update and present management controversies. Ann R Coll Surg Engl 88:433\u2013438","journal-title":"Ann R Coll Surg Engl"},{"key":"3_CR85","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/00000658-199409000-00002","volume":"220","author":"SA Wells Jr","year":"1994","unstructured":"Wells SA Jr, Chi DD, Toshima K et al (1994) Predictive DNA testing and prophylactic thyroidectomy in patients at risk for Multiple Endocrine Neoplasia Type 2A. Ann Surg 220:237\u2013250","journal-title":"Ann Surg"},{"key":"3_CR86","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1055\/s-0029-1211946","volume":"106","author":"SA Wells Jr","year":"1998","unstructured":"Wells SA Jr, Skinner MA (1998) Prophylactic thyroidectomy, based on direct genetic testing, in patients at risk for the multiple endocrine neoplasia type 2 syndromes. Exp Clin Endocrinol Diabetes 106:29\u201334","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"3_CR87","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","volume":"25","author":"SA Wells Jr","year":"2015","unstructured":"Wells SA Jr, Asa SL, Dralle H et al (2015) Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25:567\u2013610","journal-title":"Thyroid"},{"key":"3_CR88","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1001\/jamaoncol.2014.168","volume":"1","author":"S Hansford","year":"2015","unstructured":"Hansford S, Kaurah P, Li-Chang H et al (2015) Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol 1:23\u201332","journal-title":"JAMA Oncol"},{"key":"3_CR89","doi-asserted-by":"crossref","unstructured":"van der Post RS, Vogelaar IP, Carneiro F et al (2015) Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet 52:361\u201374","DOI":"10.1136\/jmedgenet-2015-103094"},{"issue":"3","key":"3_CR90","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.cgh.2005.12.003","volume":"4","author":"Vanessa Blair","year":"2006","unstructured":"Blair V, Martin I, Shaw D et al (2006) Hereditary diffuse gastric cancer: diagnosis and management. Clin Gastroenterol Hepatol 4(3):262\u201375","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"3_CR91","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1136\/jmg.2009.074237","volume":"47","author":"RC Fitzgerald","year":"2010","unstructured":"Fitzgerald RC, Hardwick R, Huntsman D et al (2010) Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet 47:436\u2013444","journal-title":"J Med Genet"},{"issue":"1","key":"3_CR92","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jmoldx.2017.09.008","volume":"20","author":"Nathan D. Montgomery","year":"2018","unstructured":"Montgomery ND, Selitsky SR, Patel NM et al (2018) Identification of germline variants in tumor Genomic sequencing analysis. J Mol Diagn 20:123\u2013125","journal-title":"The Journal of Molecular Diagnostics"},{"issue":"2","key":"3_CR93","doi-asserted-by":"publisher","first-page":"e1005965","DOI":"10.1371\/journal.pcbi.1005965","volume":"14","author":"James X. Sun","year":"2018","unstructured":"Sun JX, He Y, Sanford E et al (2018 Feb 7) A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal. PLOS Comput Biol. https:\/\/doi.org\/10.1371\/journal.pcbi.1005965","journal-title":"PLOS Computational Biology"},{"key":"3_CR94","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/gim.2013.73","volume":"15","author":"RC Green","year":"2013","unstructured":"Green RC, Berg JS, Grody WW et al (2013) ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 15:565\u2013574","journal-title":"Genet Med"},{"key":"3_CR95","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/gim.2014.151","volume":"17","author":"ACMG Board of Directors","year":"2015","unstructured":"ACMG Board of Directors (2015) ACMG policy statement: updated recommendations regarding analysis and reporting of secondary findings in clinical genome-scale sequencing. Genet Med 17:68\u201369","journal-title":"Genet Med"},{"key":"3_CR96","doi-asserted-by":"crossref","unstructured":"Kalia SS, Adelman K, Bale SJ et al (2017) Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med 19:249\u2013255","DOI":"10.1038\/gim.2016.190"},{"key":"3_CR97","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2013.03.002","volume":"153","author":"LA Garraway","year":"2013","unstructured":"Garraway LA, Lander ES (2013) Lessons from the cancer genome. Cell 153:17\u201337","journal-title":"Cell"},{"issue":"2","key":"3_CR98","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/ng.3168","volume":"47","author":"Mark D M Leiserson","year":"2014","unstructured":"Leiserson MD, Vandin F, Wu H et al (2015) Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nat Genet 47:106\u2013114","journal-title":"Nature Genetics"},{"key":"3_CR99","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/cas.13505","volume":"109","author":"H Nakagawa","year":"2018","unstructured":"Nakagawa H, Fujita M (2018) Whole genome sequencing analysis for cancer genomics and precision medicine. Cancer Sci 109:513\u2013522","journal-title":"Cancer Sci"},{"key":"3_CR100","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/ng.3547","volume":"48","author":"A Fujimoto","year":"2016","unstructured":"Fujimoto A, Furuta M, Totoki Y et al (2016) Whole genome mutational landscape and characterization of non-coding and structural mutations in liver cancer. Nat Genet 48:500\u2013509","journal-title":"Nat Genet"},{"key":"3_CR101","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/ng.2295","volume":"44","author":"WK Sung","year":"2012","unstructured":"Sung WK, Zheng H, Li S et al (2012) Genome-wide survery of recurrent HBV integration in hepatocellular carcinoma. Nat Genet 44:765\u2013769","journal-title":"Nat Genet"},{"key":"3_CR102","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/nature12881","volume":"506","author":"AI Ojesina","year":"2014","unstructured":"Ojesina AI, Lichtenstein L, Freeman SS et al (2014) Landscape of genomic alterations in cervical carcinomas. Nature 506:371\u2013375","journal-title":"Nature"},{"key":"3_CR103","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.cell.2016.04.027","volume":"165","author":"R Tewhey","year":"2016","unstructured":"Tewhey R, Kotliar D, Park DS et al (2016) Direct identification of hundreds of expression-modifying variants using a multiplexed reporter assay. Cell 165:1519\u20131529","journal-title":"Cell"},{"key":"3_CR104","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41588-018-0091-2","volume":"50","author":"W Zhang","year":"2018","unstructured":"Zhang W, Bojorquez-Gomez A, Velez DO et al (2018) A global transcriptional network connecting noncoding mutations to changes in tumor gene expression. Nat Genet 50:613\u2013620","journal-title":"Nat Genet"},{"key":"3_CR105","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.coisb.2017.02.002","volume":"2","author":"CM Johannessen","year":"2017","unstructured":"Johannessen CM, Boehm JS (2017) Progress toward precision functional genomics in cancer. Curr Opinion in Sys Biol 2:74\u201383","journal-title":"Curr Opinion in Sys Biol"},{"key":"3_CR106","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov LB, Nik-Zainal S, Wedge DC et al (2013) Signatures of mutational processes in human cancer. Nature 500:415\u2013421","journal-title":"Nature"},{"key":"3_CR107","doi-asserted-by":"publisher","first-page":"48794","DOI":"10.18632\/oncotarget.10720","volume":"8","author":"F Engert","year":"2017","unstructured":"Engert F, Kovac M, Baumhoer D, Nathrath M, Fuida S (2017) Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics. Oncotarget 8:48794\u201348806","journal-title":"Oncotarget"},{"key":"3_CR108","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong PC, Boss DS, Yap TA et al (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123\u2013134","journal-title":"N Engl J Med"},{"issue":"D1","key":"3_CR109","doi-asserted-by":"publisher","first-page":"D1036","DOI":"10.1093\/nar\/gkv1165","volume":"44","author":"Alex H. Wagner","year":"2015","unstructured":"Wagner AH, Coffman AC, Ainscough BJ et al (2016) DGIdb 2.0: mining clinically relevant drug-gene interactions. Nucleic Acids Res 44:D1036\u2013D1044","journal-title":"Nucleic Acids Research"},{"key":"3_CR110","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3747\/co.v16i2.420","volume":"16","author":"OG Scharovsky","year":"2009","unstructured":"Scharovsky OG, Mainetti LE, Rozados VR (2009) Metronomic chemotherapy: changing the paradigm that more is better. Curr Oncol 16:7\u201315","journal-title":"Curr Oncol"},{"key":"3_CR111","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1126\/science.278.5340.1064","volume":"278","author":"LH Hartwell","year":"1997","unstructured":"Hartwell LH, Szankasi P, Robets CJ, Murray AW, Friend SH (1997) Integrating genetic approaches into the discovery of anticancer drugs. Science 278:1064\u20131068","journal-title":"Science"},{"key":"3_CR112","doi-asserted-by":"crossref","first-page":"55352","DOI":"10.18632\/oncotarget.10536","volume":"7","author":"H Ye","year":"2016","unstructured":"Ye H, Zhang X, Chen Y, Liu Q, Wei J (2016) Ranking novel cancer driving synthetic lethal gene pairs using TCGA data. Oncotarget 7:55352\u201355367","journal-title":"Oncotarget"},{"issue":"7669","key":"3_CR113","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nature23477","volume":"548","author":"Shashank J. Patel","year":"2017","unstructured":"Patel SJ, Sanjana NE, Kishton RJ et al (2017) Identification of essential genes for cancer immunotherapy. Nature, 537\u2013545","journal-title":"Nature"},{"key":"3_CR114","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1084\/jem.20071985","volume":"205","author":"MH Fortier","year":"2008","unstructured":"Fortier MH, Caron E, Hardy MP et al (2008) The MHC class I peptide repertoire is molded by the transcriptome. J Exp Med 205:595\u2013610","journal-title":"J Exp Med"},{"key":"3_CR115","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/cas.13131","volume":"108","author":"T Karasaki","year":"2017","unstructured":"Karasaki T, Nagayama K, Kuwano K et al (2017) Prediction and prioritization of neoantigens: intergration of RNA sequencing data with whole-exome sequencing. Cancer Sci 108:170\u2013177","journal-title":"Cancer Sci"},{"key":"3_CR116","doi-asserted-by":"crossref","unstructured":"Wirth TC, K\u00fchnel (2017) Neoantigen targeting\u2014dawn of a new era in cancer immunotherapy. Front Immunol 8:1\u201316","DOI":"10.3389\/fimmu.2017.01848"},{"key":"3_CR117","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/nbt.3912","volume":"35","author":"KA Phillips","year":"2017","unstructured":"Phillips KA, Deverka PA, Trosman JR et al (2017) Payer coverage policies for multigene tests. Nat Biotechnol 35:614\u2013617","journal-title":"Nat Biotechnol"},{"key":"3_CR118","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1200\/JCO.2016.71.6480","volume":"35","author":"AW Kurian","year":"2017","unstructured":"Kurian AW, Li Y, Hamilton AS et al (2017) Gaps in incorporating germline genetic testing into treatment decision-making for early-stage breast cancer. J Clin Oncol 35:2232\u20132239","journal-title":"J Clin Oncol"},{"key":"3_CR119","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/gim.2013.142","volume":"15","author":"GE Merchant","year":"2013","unstructured":"Merchant GE, Lindor RA (2013) Personalized medicine and genetic malpractice. Genet Med 15:921\u2013922. https:\/\/doi.org\/10.1038\/gim.2013.142","journal-title":"Genet Med"},{"key":"3_CR120","doi-asserted-by":"crossref","unstructured":"Cerami et al (2012 May) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401","DOI":"10.1158\/2159-8290.CD-12-0095"},{"key":"3_CR121","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program populations (1969\u20132016) ( www.seer.cancer.gov\/popdata ). National Cancer Institute, DCCPS, Surveillance Research Program, released December 2017"},{"key":"3_CR122","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474(7353):609","DOI":"10.1038\/nature10166"},{"key":"3_CR123","doi-asserted-by":"crossref","unstructured":"Dougherty BA, Lai Z, Hodgson DR, Orr MC, Hawryluk M, Sun J \u2026 Fielding A (2017) Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting. Oncotarget 8(27):43653\u201343661","DOI":"10.18632\/oncotarget.17613"},{"issue":"1","key":"3_CR124","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S1470-2045(14)71135-0","volume":"16","author":"Amit M Oza","year":"2015","unstructured":"Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, \u2026 Mahner S (2015) Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol 16(1):87\u201397","journal-title":"The Lancet Oncology"},{"key":"3_CR125","doi-asserted-by":"crossref","unstructured":"Cortesi L, Toss A, Cucinotto I (2018) Parp inhibitors for the treatment of ovarian cancer. Current cancer drug targets. (Epub ahead of print)","DOI":"10.2174\/1568009618666180308104646"},{"issue":"8","key":"3_CR126","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1093\/annonc\/mdu187","volume":"25","author":"J. Balma\u00f1a","year":"2014","unstructured":"Balmana J, Tung NM, Isakoff SJ, Grana B, Ryan PD, Saura C, \u2026 Garber JE (2014) Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors. Ann Oncol 25(8):1656\u20131663","journal-title":"Annals of Oncology"},{"issue":"4","key":"3_CR127","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/bjc.2014.345","volume":"111","author":"G Del Conte","year":"2014","unstructured":"Del Conte G, Sessa C, Von Moos R, Vigano L, Digena T, Locatelli A \u2026 Gianni L (2014) Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours. Br J Cancer 111(4):651","journal-title":"British Journal of Cancer"},{"key":"3_CR128","doi-asserted-by":"crossref","unstructured":"Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski J A \u2026 Figg WD (2014) Phase I\/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. J Natl Cancer Inst 106(6), dju089","DOI":"10.1093\/jnci\/dju089"},{"issue":"22","key":"3_CR129","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"Mansoor R. Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M et al (2016) Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 375(22):2154\u20132164","journal-title":"New England Journal of Medicine"},{"key":"3_CR130","doi-asserted-by":"crossref","unstructured":"Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, \u2026 Leary A (2017) Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 390(10106):1949\u20131961","DOI":"10.1016\/S0140-6736(17)32440-6"},{"key":"3_CR131","unstructured":"Toss A, Cortesi L (2013) Molecular mechanisms of PARP inhibitors in BRCA-related ovarian cancer. J Cancer Sci Therapy 5(11):409\u2013416"},{"key":"3_CR132","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.tig.2006.06.007","volume":"22","author":"DG Albertson","year":"2006","unstructured":"Albertson DG (2006) Gene amplification in cancer. Trends Genet 22:447\u2013455","journal-title":"Trends Genet"},{"key":"3_CR133","unstructured":"Jorde, LB, Carey, JC, Bamshad MJ (2015) Medical genetics e-Book. Elsevier Health Sciences (Page 324)"},{"key":"3_CR134","doi-asserted-by":"crossref","unstructured":"Laskar BZ, Majumder S (2017) Gene expression programming. In: Bio-inspired computing for information retrieval applications. IGI Global, pp 269\u2013292 (Page 270)","DOI":"10.4018\/978-1-5225-2375-8.ch010"},{"key":"3_CR135","doi-asserted-by":"publisher","first-page":"4487","DOI":"10.1093\/nar\/gkw282","volume":"44","author":"NS Latysheva","year":"2016","unstructured":"Latysheva NS, Babu MM (2016) Discovering and understanding oncogenic gene fusions through data intensive computational approaches. Nucleic Acids Res 44:4487\u20134503","journal-title":"Nucleic Acids Res"},{"key":"3_CR136","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129\u20132139","journal-title":"N Engl J Med"},{"key":"3_CR137","unstructured":"Nussbaum RL, McInnes RR, Willard HF (2016) Thompson & Thompson genetics in medicine, 8th edn. Elsevier Health Sciences, Philadephia, pp 314\u2013502"},{"key":"3_CR138","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 17:405\u2013424","journal-title":"Genet Med."},{"issue":"5","key":"3_CR139","doi-asserted-by":"publisher","first-page":"789","DOI":"10.21037\/jgo.2016.08.12","volume":"7","author":"S Rizvi","year":"2016","unstructured":"Rizvi S, Borad MJ (2016) The rise of the FGFR inhibitor in advanced biliary cancer: the next cover of time magazine? J Gastrointest Oncol. 7(5):789\u2013796","journal-title":"J Gastrointest Oncol."},{"key":"3_CR140","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","volume":"364","author":"E Tiacci","year":"2011","unstructured":"Tiacci E, Trifonov V, Schiavoni G et al (2011) BRAF mutations in hairy-cell leukemia. N Engl J Med 364:2305\u20132315","journal-title":"N Engl J Med"}],"container-title":["Cancer Treatment and Research","Precision Medicine in Cancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-16391-4_3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T07:57:12Z","timestamp":1609919832000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-030-16391-4_3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9783030163907","9783030163914"],"references-count":140,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-16391-4_3","relation":{},"ISSN":["0927-3042","2509-8497"],"issn-type":[{"value":"0927-3042","type":"print"},{"value":"2509-8497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"18 June 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}